Systemic lupus erythematosus (Q55933861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

Systemic lupus erythematosus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

systemic lupus erythematosus

25 December 2019

main subject

0 references

2

Munther A Khamashta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

David P D'Cruz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Graham R V Hughes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

369

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

9561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

587-596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

Systemic lupus erythematosus

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Mortality and causes of death in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

SLE--a disease of clearance deficiency?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

EBV and systemic lupus erythematosus: a new perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Use of exogenous estrogens in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A trial of contraceptive methods in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Premature coronary-artery atherosclerosis in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Risk factors for cardiovascular disease in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Pulmonary hypertension in systemic lupus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Evaluation of systemic lupus erythematosus activity during pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Pregnancy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The effect of pregnancy on lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients With Systemic Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Pulmonary arterial hypertension associated to connective tissue diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Livedo reticularis and pregnancy morbidity in patients negative for antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Seronegative antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Intravenous immunoglobulin therapy and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

An international cohort study of cancer in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960279-7

7 January 2021

10.1016/S0140-6736(07)60279-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17307106%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference